Plasmapheresis therapy for rare but potentially fatal reaction to rituximab

Deborah Hastings, Bhavesh Patel, Antonio Sergio Torioni, Farouk Mookadam, Jeffrey Betcher, Adyr Moss, Raymond Heilman, Marek Mazur, Khaled Hamawi, David Mulligan, Kunam Sudhakar Reddy, Kristin Mekeel, Harini M Chakkera

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Rituximab (Rituxan), a genetically engineered chimeric murine and human IgG1 monoclonal antibody directed against CD20 antigen, is an emerging drug used for a wide spectrum of disease processes and found to be relatively safe. We report a near-fatal reaction to rituximab, which started 30 min after infusion and worsened over 24 to 48 h, resulting in hemodynamic and respiratory compromise that necessitated both intubation and high-dose vasopressors. Subsequent treatment with plasmapheresis helped stabilize and improve the patient's clinical condition, and the patient was discharged home on hospital day 5. There is no specific treatment for these severe and sometimes fatal reactions except supportive care with plasmapheresis. With the increased use of rituximab therapy in the medical management of numerous diseases, those in the medical community need to be cognizant of the rare fatal or near-fatal infusion reaction and the benefit that may accrue from plasmapheresis therapy.

Original languageEnglish (US)
Pages (from-to)28-31
Number of pages4
JournalJournal of Clinical Apheresis
Volume24
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Plasmapheresis
CD20 Antigens
Therapeutics
Disease Management
Intubation
Immunoglobulin G
Hemodynamics
Monoclonal Antibodies
Rituximab
Pharmaceutical Preparations

Keywords

  • Antibodies
  • Antigens
  • CD20
  • Hematological neoplasms
  • Monoclonal

ASJC Scopus subject areas

  • Hematology

Cite this

Plasmapheresis therapy for rare but potentially fatal reaction to rituximab. / Hastings, Deborah; Patel, Bhavesh; Torioni, Antonio Sergio; Mookadam, Farouk; Betcher, Jeffrey; Moss, Adyr; Heilman, Raymond; Mazur, Marek; Hamawi, Khaled; Mulligan, David; Reddy, Kunam Sudhakar; Mekeel, Kristin; Chakkera, Harini M.

In: Journal of Clinical Apheresis, Vol. 24, No. 1, 2009, p. 28-31.

Research output: Contribution to journalArticle

Hastings, D, Patel, B, Torioni, AS, Mookadam, F, Betcher, J, Moss, A, Heilman, R, Mazur, M, Hamawi, K, Mulligan, D, Reddy, KS, Mekeel, K & Chakkera, HM 2009, 'Plasmapheresis therapy for rare but potentially fatal reaction to rituximab', Journal of Clinical Apheresis, vol. 24, no. 1, pp. 28-31. https://doi.org/10.1002/jca.20187
Hastings D, Patel B, Torioni AS, Mookadam F, Betcher J, Moss A et al. Plasmapheresis therapy for rare but potentially fatal reaction to rituximab. Journal of Clinical Apheresis. 2009;24(1):28-31. https://doi.org/10.1002/jca.20187
Hastings, Deborah ; Patel, Bhavesh ; Torioni, Antonio Sergio ; Mookadam, Farouk ; Betcher, Jeffrey ; Moss, Adyr ; Heilman, Raymond ; Mazur, Marek ; Hamawi, Khaled ; Mulligan, David ; Reddy, Kunam Sudhakar ; Mekeel, Kristin ; Chakkera, Harini M. / Plasmapheresis therapy for rare but potentially fatal reaction to rituximab. In: Journal of Clinical Apheresis. 2009 ; Vol. 24, No. 1. pp. 28-31.
@article{cbab4402a0c2416891e28c98bd411b55,
title = "Plasmapheresis therapy for rare but potentially fatal reaction to rituximab",
abstract = "Rituximab (Rituxan), a genetically engineered chimeric murine and human IgG1 monoclonal antibody directed against CD20 antigen, is an emerging drug used for a wide spectrum of disease processes and found to be relatively safe. We report a near-fatal reaction to rituximab, which started 30 min after infusion and worsened over 24 to 48 h, resulting in hemodynamic and respiratory compromise that necessitated both intubation and high-dose vasopressors. Subsequent treatment with plasmapheresis helped stabilize and improve the patient's clinical condition, and the patient was discharged home on hospital day 5. There is no specific treatment for these severe and sometimes fatal reactions except supportive care with plasmapheresis. With the increased use of rituximab therapy in the medical management of numerous diseases, those in the medical community need to be cognizant of the rare fatal or near-fatal infusion reaction and the benefit that may accrue from plasmapheresis therapy.",
keywords = "Antibodies, Antigens, CD20, Hematological neoplasms, Monoclonal",
author = "Deborah Hastings and Bhavesh Patel and Torioni, {Antonio Sergio} and Farouk Mookadam and Jeffrey Betcher and Adyr Moss and Raymond Heilman and Marek Mazur and Khaled Hamawi and David Mulligan and Reddy, {Kunam Sudhakar} and Kristin Mekeel and Chakkera, {Harini M}",
year = "2009",
doi = "10.1002/jca.20187",
language = "English (US)",
volume = "24",
pages = "28--31",
journal = "Journal of Clinical Apheresis",
issn = "0733-2459",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Plasmapheresis therapy for rare but potentially fatal reaction to rituximab

AU - Hastings, Deborah

AU - Patel, Bhavesh

AU - Torioni, Antonio Sergio

AU - Mookadam, Farouk

AU - Betcher, Jeffrey

AU - Moss, Adyr

AU - Heilman, Raymond

AU - Mazur, Marek

AU - Hamawi, Khaled

AU - Mulligan, David

AU - Reddy, Kunam Sudhakar

AU - Mekeel, Kristin

AU - Chakkera, Harini M

PY - 2009

Y1 - 2009

N2 - Rituximab (Rituxan), a genetically engineered chimeric murine and human IgG1 monoclonal antibody directed against CD20 antigen, is an emerging drug used for a wide spectrum of disease processes and found to be relatively safe. We report a near-fatal reaction to rituximab, which started 30 min after infusion and worsened over 24 to 48 h, resulting in hemodynamic and respiratory compromise that necessitated both intubation and high-dose vasopressors. Subsequent treatment with plasmapheresis helped stabilize and improve the patient's clinical condition, and the patient was discharged home on hospital day 5. There is no specific treatment for these severe and sometimes fatal reactions except supportive care with plasmapheresis. With the increased use of rituximab therapy in the medical management of numerous diseases, those in the medical community need to be cognizant of the rare fatal or near-fatal infusion reaction and the benefit that may accrue from plasmapheresis therapy.

AB - Rituximab (Rituxan), a genetically engineered chimeric murine and human IgG1 monoclonal antibody directed against CD20 antigen, is an emerging drug used for a wide spectrum of disease processes and found to be relatively safe. We report a near-fatal reaction to rituximab, which started 30 min after infusion and worsened over 24 to 48 h, resulting in hemodynamic and respiratory compromise that necessitated both intubation and high-dose vasopressors. Subsequent treatment with plasmapheresis helped stabilize and improve the patient's clinical condition, and the patient was discharged home on hospital day 5. There is no specific treatment for these severe and sometimes fatal reactions except supportive care with plasmapheresis. With the increased use of rituximab therapy in the medical management of numerous diseases, those in the medical community need to be cognizant of the rare fatal or near-fatal infusion reaction and the benefit that may accrue from plasmapheresis therapy.

KW - Antibodies

KW - Antigens

KW - CD20

KW - Hematological neoplasms

KW - Monoclonal

UR - http://www.scopus.com/inward/record.url?scp=63249135067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249135067&partnerID=8YFLogxK

U2 - 10.1002/jca.20187

DO - 10.1002/jca.20187

M3 - Article

C2 - 19156754

AN - SCOPUS:63249135067

VL - 24

SP - 28

EP - 31

JO - Journal of Clinical Apheresis

JF - Journal of Clinical Apheresis

SN - 0733-2459

IS - 1

ER -